Healthcare - Biotechnology - NASDAQ - US
$ 0.0959
-8.32 %
$ 10.4 M
Market Cap
-0.64
P/E
CASH FLOW STATEMENT
-43.2 M
OPERATING CASH FLOW
21.4 M
INVESTING CASH FLOW
21.2 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Apollomics, Inc.
| Net Income | -173 M |
| Depreciation & Amortization | 669 K |
| Capital Expenditures | -6 K |
| Stock-Based Compensation | 12.7 M |
| Change in Working Capital | -3.57 M |
| Others | 116 M |
| Free Cash Flow | -43.2 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (172.6) | (240.8) | (94.8) | (74.9) | (45.9) |
| Depreciation & Amortization | 0.7 | 0.8 | 0.7 | 0.6 | 0.4 |
| Deferred Income Tax | 0 | 0.4 | 40.4 | 27.5 | 0 |
| Stock Based Compensation | 12.7 | 3.6 | 8.1 | 4.5 | 0 |
| Other Operating Activities | 119.6 | 186.7 | (0.4) | 3.5 | 23.2 |
| Change in Working Capital | (3.6) | 6.5 | 2.6 | 3.1 | 1.1 |
| Cash From Operations | (43.2) | (42.8) | (43.3) | (35.7) | (21.9) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 6 K | (0.4) | (7.5) | (10.1) | (0.9) |
| Other Items | 21.4 | 29.4 | (31.4) | 12.5 | (29.0) |
| Cash From Investing Activities | 21.4 | 29.1 | (39.0) | 2.3 | (29.9) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 24.0 | (0.6) | 0 | (0.5) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.8) | 93 K | (1.8) | 120.0 | (0.3) |
| Cash From Financing Activities | 21.2 | (0.3) | (1.6) | 125.5 | 9.5 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (0.6) | (14.1) | (83.9) | 92.2 | (42.3) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (43.2) | (43.2) | (50.9) | (45.8) | (22.8) |